Buprenorphine transdermal - Samyang

Drug Profile

Buprenorphine transdermal - Samyang

Latest Information Update: 01 Dec 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Samyang Group
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer pain; Postoperative pain

Most Recent Events

  • 29 Nov 2005 Buprenorphine is available for licensing(http://www.samyangpharm.com)
  • 29 Nov 2005 Phase-I clinical trials in Cancer pain in South Korea (Transdermal)
  • 29 Nov 2005 Phase-I clinical trials in Postoperative pain in South Korea (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top